What are the key findings of Roybal et al. 2016 regarding the therapeutic use of engineered T cells?

Zenodo (CERN European Organization for Nuclear Research) 2026 Open access

Read full text
Authors: Tripdatabase
DOI: 10.5281/zenodo.18396390
Cited by: 0

Abstract

Roybal et al. (2016) underscore the potential of CAR T-cell therapy in treating B-cell malignancies, highlighting high response rates and manageable adverse effects, though there are uncertainties in long-term safety and efficacy.

Fields of Study & Subjects

CAR-T cell therapy research Immunotherapy and Immune Responses T-cell and B-cell Immunology

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
28 January 2026